Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

738.00 -6.50 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
42 43 Next >
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
Via Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
The U.S. 
Via Benzinga
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart
If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish... 
Via Benzinga
7 Best Healthcare Stocks to Buy Now
The move toward treating DNA as akin to a programming language is just getting started, but you can start profiting on healthcare stocks now. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review
The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in... 
Via Benzinga
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
More than four in 10 people in a recent survey knew of someone with long Covid. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange... 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.08%. Currently, Regeneron... 
Via Benzinga
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
Image provided by Pexels 
Via Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
The U.S. 
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Stock Market Rally Falls As Fed Signals More Big Rate Hikes; Salesforce, Tesla In Focus: Weekly Review
Stocks fell modestly on hawkish Fed comments, but the Nasdaq held its 21-day line. 
Via Investor's Business Daily
Markets Rise Amid Strength In Tech, Software
U.S. indices finished Thursday’s trading session higher. Overall tech and software sector strength as well as strong first-quarter results from Mongodb Inc (NASDAQ: MDB) lifted markets higher for the... 
Via Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
Regeneron secured the global rights to Sanofi-partnered Libtayo. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
7 Analysts Have This to Say About Regeneron Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/31/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Regeneron Pharmaceuticals, Inc. 
Via SBWire
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.